Early Joint Clearance With Bimekizumab Leads to Durable Disease Control in PsAByLaure Gossec, MD, PhDJune 10th 2026
Autoantibody and IFN Burden Correlate With Nipocalimab Response in Sjögren's DiseaseByR. Hal Scofield, MDJune 10th 2026
Nerandomilast Slows Lung Function Decline, Reduces Mortality Risk in Autoimmune ILD SubgroupByPatrick CampbellJune 10th 2026
OLINGUITO: Filgotinib Meets Phase 3 Primary Endpoint in r/nr-axSpA, With Xenofon Baraliakos, MD, PhDByXenofon Baraliakos, MD, PhDJune 8th 2026
Bimekizumab Beats Risankizumab on ACR50 in First IL-17A/F vs IL-23 Head-to-HeadByPhilip J. Mease, MDJune 8th 2026